---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-037497"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:11:15.603205+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review

## Summary
- Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.
- Operating expenses fell to $5.8M in 2025 from $10.8M in 2024.
- Cash and cash equivalents $762k as of Dec 31, 2025; $2.0M in digital asset treasury.
- Board initiated evaluation of strategic alternatives on March 25, 2026; no timetable set.
- TAEUS Liver feasibility study showed r=0.89 correlation with MRI-PDFF for liver fat.

## SEC filing metadata
- accession: 0001213900-26-037497
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/0001213900-26-037497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/ea0284372-8k_endralife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-037497
- JSON: https://secwatch.observer/filing/0001213900-26-037497.json
- Plain text: https://secwatch.observer/filing/0001213900-26-037497.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2025 results: net income net loss of $3.2 million.
  - Period: the quarter and year ended December 31, 2025
  - Net income: net loss of $3.2 million
  - Result: reported results
  source text: in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024. 2025 Financial Results During 2025 the Company benefitted from actions taken throughout 2024 to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000121390026037497/0001213900-26-037497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.